Junzhe Huang MS , Changhui Lei MBBS , David H. Hsi MD , Minjuan Zheng MD, PhD , Hui Ma MBBS , Shengjun Ta MBBS , Rui Hu MS , Chao Han MD, PhD , Wenxia Li MBBS , Jing Li MBBS , Dong Qu MBBS , Fangqi Ruan PhD , Jing Wang MD, PhD , Bo Wang MBBS , Xueli Zhao MBBS , Jiao Liu PhD , Lina Zhao MD, PhD , Zhe Wang MD, PhD , Jian Yang MD, PhD , Liwen Liu MD, PhD
{"title":"超声心动图引导下的心脏肿瘤射频消融术","authors":"Junzhe Huang MS , Changhui Lei MBBS , David H. Hsi MD , Minjuan Zheng MD, PhD , Hui Ma MBBS , Shengjun Ta MBBS , Rui Hu MS , Chao Han MD, PhD , Wenxia Li MBBS , Jing Li MBBS , Dong Qu MBBS , Fangqi Ruan PhD , Jing Wang MD, PhD , Bo Wang MBBS , Xueli Zhao MBBS , Jiao Liu PhD , Lina Zhao MD, PhD , Zhe Wang MD, PhD , Jian Yang MD, PhD , Liwen Liu MD, PhD","doi":"10.1016/j.jaccao.2024.03.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Patients with cardiac tumors may present challenges for surgical resection due to poor clinical condition. Echocardiography-guided transapical radiofrequency ablation for cardiac tumors (TARFACT) potentially offers a less invasive palliative therapy option.</p></div><div><h3>Objectives</h3><p>This study aimed to evaluate the safety and efficacy of TARFACT.</p></div><div><h3>Methods</h3><p>Five patients with cardiac tumors (mucinous liposarcoma, myocardial hypertrophy with inflammatory cell infiltration mass, fibrous tissue tumor hyperplasia, myocardial clear cell sarcoma, and cardiac rhabdomyoma) were included. All patients underwent TARFACT and were assessed with electrocardiogram, echocardiographic imaging, biochemical analysis, and pathological confirmation.</p></div><div><h3>Results</h3><p>The median follow-up for all patients was 9 (range 4-12) months. Three surviving patients were alive at their last follow-up (9, 12, and 12 months, respectively), whereas 2 patients with late-stage tumors survived 6 months and 13 months after TARFACT, respectively. After TARFACT, all patients showed significant reductions in tumor size: the mean length decreased from 6.7 ± 2.0 cm to 4.7 ± 1.8 cm (<em>P</em> = 0.007); and the mean width decreased from 5.0 ± 2.1 cm to 2.5 ± 0.7 cm (<em>P</em> = 0.041). NYHA functional class also improved: median (IQR) decreased from 3.0 (1.5) to 2.0 (1.0) (<em>P</em> = 0.038), Peak E-wave on echocardiography showed a mean increase from 64.4 ± 15.7 cm/s to 76.6 ± 18.6 cm/s (<em>P</em> = 0.008), and NT-pro BNP levels had a median (IQR) reduction from 115.7 (252.1) pg/mL to 55.0 (121.6) pg/mL (<em>P</em> = 0.043).</p></div><div><h3>Conclusions</h3><p>TARFACT is a novel palliative treatment option for cardiac tumors, reducing accessible tumors and improving clinical symptoms in a preliminary group of patients. (Cardiac Tumors Interventional [Radio Frequency/Laser Ablation] Therapy [CTIH]; <span><span>NCT02815553</span><svg><path></path></svg></span>)</p></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 560-571"},"PeriodicalIF":12.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324001406/pdfft?md5=d5e348eb1c82c9980ac1986cd5c8798a&pid=1-s2.0-S2666087324001406-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Echocardiography-Guided Radiofrequency Ablation for Cardiac Tumors\",\"authors\":\"Junzhe Huang MS , Changhui Lei MBBS , David H. Hsi MD , Minjuan Zheng MD, PhD , Hui Ma MBBS , Shengjun Ta MBBS , Rui Hu MS , Chao Han MD, PhD , Wenxia Li MBBS , Jing Li MBBS , Dong Qu MBBS , Fangqi Ruan PhD , Jing Wang MD, PhD , Bo Wang MBBS , Xueli Zhao MBBS , Jiao Liu PhD , Lina Zhao MD, PhD , Zhe Wang MD, PhD , Jian Yang MD, PhD , Liwen Liu MD, PhD\",\"doi\":\"10.1016/j.jaccao.2024.03.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Patients with cardiac tumors may present challenges for surgical resection due to poor clinical condition. Echocardiography-guided transapical radiofrequency ablation for cardiac tumors (TARFACT) potentially offers a less invasive palliative therapy option.</p></div><div><h3>Objectives</h3><p>This study aimed to evaluate the safety and efficacy of TARFACT.</p></div><div><h3>Methods</h3><p>Five patients with cardiac tumors (mucinous liposarcoma, myocardial hypertrophy with inflammatory cell infiltration mass, fibrous tissue tumor hyperplasia, myocardial clear cell sarcoma, and cardiac rhabdomyoma) were included. All patients underwent TARFACT and were assessed with electrocardiogram, echocardiographic imaging, biochemical analysis, and pathological confirmation.</p></div><div><h3>Results</h3><p>The median follow-up for all patients was 9 (range 4-12) months. Three surviving patients were alive at their last follow-up (9, 12, and 12 months, respectively), whereas 2 patients with late-stage tumors survived 6 months and 13 months after TARFACT, respectively. After TARFACT, all patients showed significant reductions in tumor size: the mean length decreased from 6.7 ± 2.0 cm to 4.7 ± 1.8 cm (<em>P</em> = 0.007); and the mean width decreased from 5.0 ± 2.1 cm to 2.5 ± 0.7 cm (<em>P</em> = 0.041). NYHA functional class also improved: median (IQR) decreased from 3.0 (1.5) to 2.0 (1.0) (<em>P</em> = 0.038), Peak E-wave on echocardiography showed a mean increase from 64.4 ± 15.7 cm/s to 76.6 ± 18.6 cm/s (<em>P</em> = 0.008), and NT-pro BNP levels had a median (IQR) reduction from 115.7 (252.1) pg/mL to 55.0 (121.6) pg/mL (<em>P</em> = 0.043).</p></div><div><h3>Conclusions</h3><p>TARFACT is a novel palliative treatment option for cardiac tumors, reducing accessible tumors and improving clinical symptoms in a preliminary group of patients. (Cardiac Tumors Interventional [Radio Frequency/Laser Ablation] Therapy [CTIH]; <span><span>NCT02815553</span><svg><path></path></svg></span>)</p></div>\",\"PeriodicalId\":48499,\"journal\":{\"name\":\"Jacc: Cardiooncology\",\"volume\":\"6 4\",\"pages\":\"Pages 560-571\"},\"PeriodicalIF\":12.0000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666087324001406/pdfft?md5=d5e348eb1c82c9980ac1986cd5c8798a&pid=1-s2.0-S2666087324001406-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Jacc: Cardiooncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666087324001406\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jacc: Cardiooncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666087324001406","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Echocardiography-Guided Radiofrequency Ablation for Cardiac Tumors
Background
Patients with cardiac tumors may present challenges for surgical resection due to poor clinical condition. Echocardiography-guided transapical radiofrequency ablation for cardiac tumors (TARFACT) potentially offers a less invasive palliative therapy option.
Objectives
This study aimed to evaluate the safety and efficacy of TARFACT.
Methods
Five patients with cardiac tumors (mucinous liposarcoma, myocardial hypertrophy with inflammatory cell infiltration mass, fibrous tissue tumor hyperplasia, myocardial clear cell sarcoma, and cardiac rhabdomyoma) were included. All patients underwent TARFACT and were assessed with electrocardiogram, echocardiographic imaging, biochemical analysis, and pathological confirmation.
Results
The median follow-up for all patients was 9 (range 4-12) months. Three surviving patients were alive at their last follow-up (9, 12, and 12 months, respectively), whereas 2 patients with late-stage tumors survived 6 months and 13 months after TARFACT, respectively. After TARFACT, all patients showed significant reductions in tumor size: the mean length decreased from 6.7 ± 2.0 cm to 4.7 ± 1.8 cm (P = 0.007); and the mean width decreased from 5.0 ± 2.1 cm to 2.5 ± 0.7 cm (P = 0.041). NYHA functional class also improved: median (IQR) decreased from 3.0 (1.5) to 2.0 (1.0) (P = 0.038), Peak E-wave on echocardiography showed a mean increase from 64.4 ± 15.7 cm/s to 76.6 ± 18.6 cm/s (P = 0.008), and NT-pro BNP levels had a median (IQR) reduction from 115.7 (252.1) pg/mL to 55.0 (121.6) pg/mL (P = 0.043).
Conclusions
TARFACT is a novel palliative treatment option for cardiac tumors, reducing accessible tumors and improving clinical symptoms in a preliminary group of patients. (Cardiac Tumors Interventional [Radio Frequency/Laser Ablation] Therapy [CTIH]; NCT02815553)
期刊介绍：
JACC: CardioOncology is a specialized journal that belongs to the esteemed Journal of the American College of Cardiology (JACC) family. Its purpose is to enhance cardiovascular care for cancer patients by publishing high-quality, innovative scientific research and sharing evidence-based knowledge.
The journal aims to revolutionize the field of cardio-oncology and actively involve and educate professionals in both cardiovascular and oncology fields. It covers a wide range of topics including pre-clinical, translational, and clinical research, as well as best practices in cardio-oncology. Key areas of focus include understanding disease mechanisms, utilizing in vitro and in vivo models, exploring novel and traditional therapeutics (across Phase I-IV trials), studying epidemiology, employing precision medicine, and investigating primary and secondary prevention.
Amyloidosis, cardiovascular risk factors, heart failure, and vascular disease are some examples of the disease states that are of particular interest to the journal. However, it welcomes research on other relevant conditions as well.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
